Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor
about
The DAN family: modulators of TGF-β signaling and beyondβ3 Integrin Promotes Long-Lasting Activation and Polarization of Vascular Endothelial Growth Factor Receptor 2 by Immobilized Ligand.Canonical and noncanonical vascular endothelial growth factor pathways: new developments in biology and signal transduction.Role of the TGF-β/BMP-7/Smad pathways in renal diseasesPrognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma.Overexpression of Gremlin-1 in patients with Loeys-Dietz syndrome: implications on pathophysiology and early disease detection.Identification of a gene expression driven progression pathway in myxoid liposarcoma.Gremlin is overexpressed in lung adenocarcinoma and increases cell growth and proliferation in normal lung cells.Gremlin induces cell proliferation and extra cellular matrix accumulation in mouse mesangial cells exposed to high glucose via the ERK1/2 pathwayConditional deletion of gremlin causes a transient increase in bone formation and bone mass.Gremlin, a bone morphogenetic protein antagonist, is a crucial angiogenic factor in pituitary adenoma.Bone morphogenetic protein modulator BMPER is highly expressed in malignant tumors and controls invasive cell behavior.Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosisAllelic depletion of grem1 attenuates diabetic kidney disease.Monomeric gremlin is a novel vascular endothelial growth factor receptor-2 antagonist.New insights into bone morphogenetic protein signaling: focus on angiogenesis.Role of gremlin in the lung: development and disease.Molecular mechanisms of endothelial differentiation.Bone Morphogenetic Protein functions as a context-dependent angiogenic cue in vertebrates.BMPs are mediators in tissue crosstalk of the regenerating musculoskeletal system.Bone morphogenetic protein-4: a novel therapeutic target for pathological cardiac hypertrophy/heart failure.Generation and Applications of a DNA Aptamer against Gremlin-1.Heparin/Heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use.Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1.Endothelial Nox1 oxidase assembly in human pulmonary arterial hypertension; driver of Gremlin1-mediated proliferation.Gremlin regulates renal inflammation via the vascular endothelial growth factor receptor 2 pathway.Agonists and Antagonists of TGF-β Family Ligands.Tumor angiogenesis revisited: Regulators and clinical implications.Bone Morphogenic Protein Type 2 Receptor Mutation-Independent Mechanisms of Disrupted Bone Morphogenetic Protein Signaling in Idiopathic Pulmonary Arterial Hypertension.A functional variant in GREM1 confers risk for colorectal cancer by disrupting a hsa-miR-185-3p binding site.Fibroblast growth factor 2-induced angiogenesis in zebrafish: the zebrafish yolk membrane (ZFYM) angiogenesis assay.Multi-physics interactions drive VEGFR2 relocation on endothelial cells.The Dual Role of Bone Morphogenetic Proteins in Cancer.Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors.Gremlin and renal diseases: ready to jump the fence to clinical utility?Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis.Intrinsic BMP Antagonist Gremlin-1 as a Novel Circulating Marker in Pulmonary Arterial Hypertension.REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature.Tubular overexpression of Gremlin in transgenic mice aggravates renal damage in diabetic nephropathy.Overexpression of Gremlin1 in Mesenchymal Stem Cells Improves Hindlimb Ischemia in Mice by Enhancing Cell Survival.
P2860
Q27025762-C5F80D3C-F45B-49C3-BD56-AFB3FA2E6DF7Q27342136-BDF39C3A-57E6-4A8E-962B-EE7334340B3DQ27342723-CA1DEC15-D734-44B7-83B1-54F089BE071EQ28278757-CEF11B1B-596A-456E-A4A1-E02B95849FCBQ33597062-0E01AC92-7663-4CE0-B677-76F6F4980CADQ34035163-B86257F7-028B-401A-88D6-AE2187586936Q34227540-BC05AE70-22F5-41DD-BDDD-DA71A5D44184Q34369398-FE078993-810B-460D-9FC2-9C6867C1E163Q34581271-38B2918E-F608-4FE0-B91D-94AC241EC95DQ34676851-E8423A81-76AB-478D-A816-F78217F63378Q35193538-252D6346-6AF3-4398-82D5-6499F9A3FA3CQ36035290-430FCAD4-AB13-456C-B844-C713FFB28F29Q36414883-D8F810D4-3178-4504-B0E8-CB245FF6ABADQ37236273-DF049438-9932-4E97-94CA-AFE61D39B4D7Q37376551-DFA593EE-8B56-49DF-9102-9376A86ECA04Q37433692-3F30386E-3917-4AF5-83EF-7DF94603808FQ37539508-1996E3D8-324B-4E49-8D70-859E47458F8BQ37771779-FBF59D79-0989-4E27-8C80-2F0801E04490Q37947050-54F120FA-97B0-4A77-B7F5-94D1B63603D4Q37983414-8F8916F4-3C54-44EE-8894-1BB7F2A84425Q38204900-90CBE73E-8395-4620-AAF6-FA7C0524CAC3Q38288247-B7D16A2E-A2D7-4BB6-8DCF-2E15CC78EB0FQ38418286-9185646E-4A55-45A6-99E1-0329CDAF6917Q38490347-AB998F05-6EEF-4929-B7C0-2AFEB87F4E1FQ38776018-2C6357F1-EAB0-45BA-9ED7-8FCA5C0CC3AEQ38895003-1CEE1BE0-6AAB-468C-A2DC-E2705D01D641Q38896053-6DBA0E92-391F-4A9D-84B2-A9DEE4FB3B5EQ39393740-3D4B8E11-6CCE-4B9F-A4E1-7876D77B2D0DQ39760107-3C4E15B0-3DB2-4345-8D85-5FDB0017CEB0Q42365271-A3DCEC0C-6FEE-4EA7-B94C-BAAB02726BBDQ46461130-71F9B959-8583-4A4F-B872-58E4A12BC51AQ47131330-52AFC8C1-2848-41C6-ABF1-DA7204A07DC1Q47163689-3E9F2B47-92E5-4227-8DB4-291EB185018FQ47611708-70D61EF7-0423-47D9-83A0-EBADB44D4847Q47676484-2B55FE06-3087-47B6-AE99-446A15621FECQ47983641-3A01561A-8FDB-44F6-87EB-314CF0074BCCQ48201616-DE0D9081-65AE-4517-B87F-D11EF2B6A538Q49562927-540EA00E-BBAE-49B7-9629-285070D713FBQ50440958-638C8397-8679-4ED1-8CCA-3B6DE49BEB24Q51178261-4E03EC7F-52EF-4572-9891-367282A585E6
P2860
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor
description
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2007
@ast
im März 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2007/03/01)
@sk
vědecký článek publikovaný v roce 2007
@cs
wetenschappelijk artikel (gepubliceerd op 2007/03/01)
@nl
наукова стаття, опублікована в березні 2007
@uk
مقالة علمية (نشرت في مارس 2007)
@ar
name
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor
@ast
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor
@en
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor
@nl
type
label
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor
@ast
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor
@en
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor
@nl
prefLabel
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor
@ast
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor
@en
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor
@nl
P2093
P3181
P1433
P1476
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor
@en
P2093
Antonello Pessi
Daniela Coltrini
David Waltregny
Emanuela Moroni
Fabio Talamo
Francesco Peri
Franco Cotelli
Helena Stabile
Laura Orsatti
Marco Presta
P304
P3181
P356
10.1182/BLOOD-2006-06-032276
P407
P577
2007-03-01T00:00:00Z